In contrast, HER2 amplification occurs in approximately 40 % of IBCs [29, 30], and IBC patients with HER2-amplified tumors have been shown to respond favorably to anti-HER2 therapies [31]. This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.